Vectus Biosystems Limited (ASX:VBS)

Market Cap	4.26M
Revenue (ttm)	884.21K
Net Income (ttm)	-2.26M
Shares Out	53.28M
EPS (ttm)	-0.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	760
Average Volume	87
Open	0.0800
Previous Close	0.0800
Day's Range	0.0800 - 0.0800
52-Week Range	0.0750 - 0.2750
Beta	1.04
RSI	89.18
Earnings Date	May 22, 2025

About Vectus Biosystems

Vectus Biosystems Limited engages in the medical research and development activities in Australia. The company develops treatment for cardiovascular fibrosis and systolic blood pressure, as well as treatments for kidney, liver, and lung fibrosis. Its lead compound is VB0004, currently under phase Ib clinical human trial, which is aimed at treating the loss of functional tissue to fibrosis, scarring, and high blood pressure; VB4-A32 for the treatment of liver fibrosis; VB4-A79 for the treatment of lung fibrosis; and VB4-P5 for the treatment of r...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2005
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: VBS

Financial Performance

In 2024, Vectus Biosystems's revenue was 1.14 million, a decrease of -15.94% compared to the previous year's 1.35 million. Losses were -2.34 million, -32.07% less than in 2023.